GSP Crop Science Q3 and 9M FY26: B2C brand push lifts nine-month margins despite a weak quarter

GSP Crop Science Limited presented results for the third quarter and nine months ended December 31, 2025. The headline picture is mixed. On a consolidated basis, nine-month revenue rose 14 percent year-on-year to INR 11,146 million, while EBITDA grew 32 percent to INR 1,538 million and PAT increased 26 percent to INR 751 million. Margins also improved, with nine-month EBITDA margin moving up to 13.80 percent from 11.92 percent in the prior year period.

But the quarter itself stayed under pressure on profitability. Consolidated PAT in Q3 FY26 was negative at minus INR 60 million, similar to Q3 FY25 at minus INR 62 million. This creates a familiar agrochemicals pattern where the nine-month trend looks healthy, while an individual quarter can be volatile.

Management attributed the nine-month revenue growth mainly to an increase in domestic B2C business. The presentation also linked the growth to specific brands and new product traction, which is helpful context even though a full segmental revenue split was not provided.

Domestic B2C traction shows up in product callouts

The company operates across insecticides, herbicides, fungicides and plant growth regulators, with a domestic footprint spanning 23 states and exports across 37 countries. Within domestic operations, it runs both B2B and B2C businesses in technicals and formulations.

For 9M FY26, the presentation states that B2C revenues rose due to new product sales of INR 366.00 million. It also highlighted higher sales in a set of brands: PCT-410 increased by INR 80.00 million, Torch by INR 107.00 million, Aurthor by INR 90.00 million, and Runout by INR 47.00 million. These data points indicate that growth is not being described only in broad terms, but also through identifiable product-level movement.

On the operating side, the company reported a domestic geographic expansion into Kerala, starting with one territory under the Tamil Nadu region and focusing on plantation crops. This is a small but clear distribution expansion in the B2C context.

Exports and registrations remain a core growth lever

GSP Crop Science reported a global presence across the Americas, Africa, the Middle East, and Asia Pacific, operating in 37 countries. The presentation states that international business revenue increased 20 percent over last year, driven by planned sales of products in Brazil, the USA, and the Africa region.

A specific example given was Brazil, where a registration received last year for Chlorpyriphos contributed to better sales. The company also stated it has initiated product and source registrations across Brazil, Africa, the Middle East, and Asian countries to increase its offerings in the future. During the period, registration focus was stated to be on Chlorantraniliprole and Methoxyfenzoide.

Although this is not formal financial guidance, it is a forward-looking operational signal. In agrochemicals, registrations are a practical bottleneck and often determine how quickly a company can expand its product basket and enter new markets.

Manufacturing scale and R&D depth underpin the strategy

The company positions itself as a diversified agrochemical player with strong in-house R&D and a sizable IP portfolio. It reported 102 granted patents and 108 patent applications under process, along with 10 exclusive process patents for technical products. It also highlighted capability in complex chemistries, citing Chlorantraniliprole, Clothianidin, and Pymetrozine technicals.

On the manufacturing side, GSP Crop Science reported five operating manufacturing facilities in India. Installed capacities disclosed were:

• Odhav: formulations 27,132.00 MT; technicals 3,960.00 MT
• Kathwada: formulations 6,000.00 MT
• Nandesari: technicals 11,160.00 MT
• Samba: formulations 10,540.00 MT
• Saykha: intermediates 5,400 MT

The company also listed certifications ISO 9001:2015, ISO 14001:2015, and ISO 45001:2018, which indicates standardized systems for quality, environment, and occupational safety.

In Synthesis R&D, the company stated it initiated work on two insecticides and one herbicide active ingredients from an IP perspective, aiming for early entry when patents expire in the near future. It also applied for 10 technical registrations for export only and received approval for some, with others in progress. Additionally, it filed eight technical molecule registrations under sections 9(4) and 9(3), with some approved and others in progress.

Financial snapshot: nine-month improvement, quarter-level volatility

The consolidated and standalone disclosures both show improvement at the nine-month level, alongside a weaker Q3 profitability outcome.

The key margin takeaway is that nine-month EBITDA margins expanded on both views. Consolidated EBITDA margin increased to 13.80 percent from 11.92 percent. Standalone EBITDA margin increased to 11.01 percent from 9.79 percent.

At the same time, the presentation does not provide an explicit explanation for the Q3 loss. Without that commentary, it is difficult to isolate whether Q3 weakness was driven by seasonality, product mix, pricing pressure, or other costs. Investors would typically look for additional details on this point.

What stands out from this presentation

The document makes three clear points. First, management attributes nine-month growth mainly to the domestic B2C segment and supports this claim with product-level incremental sales figures, including a stated INR 366 million of new product sales and higher sales in PCT-410, Torch, Aurthor, and Runout.

Second, the company continues to emphasize its registrations and IP base. It reported 288 registrations domestically across formulations and technicals, alongside export registrations for 176 formulations and 60 technical product registrations. It also disclosed a large patent portfolio and stated capability in complex technical chemistries.

Third, while nine-month profitability improved, quarter-level volatility is visible, with losses in Q3 PAT on both consolidated and standalone bases. The absence of a segment-wise revenue split and the lack of a Q3 profit bridge are the main disclosure gaps in this specific presentation.

Overall, GSP Crop Science’s nine-month trend suggests improving margins driven by higher B2C volumes, while the quarterly profit volatility remains a key area that would need deeper explanation through concall commentary or future disclosures.